C-terminal bromodomain of human BRD2 in complex with 4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole inhibitor

C-terminal bromodomain of human BRD2 in complex with 4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole inhibitor Descriptor: 4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole, Bromodomain-containing protein 2, GLYCEROL Authors: Lansdon, E.B, Newby, Z.E.R. Deposit date: 2018-10-04 Release date: 2019-01-23 Last modified: 2024-03-13 Method: X-RAY DIFFRACTION (1.271 Å) Cite: Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor. Bioorg. Med. Chem., 27, 2019

人BRD2的C端溴结构域（bromodomain）与4-(2-环丙基-7-(6-甲基喹啉-5-基)-1H-苯并[d]咪唑-5-基)-3,5-二甲基异恶唑抑制剂形成的复合物。配体描述：4-(2-环丙基-7-(6-甲基喹啉-5-基)-1H-苯并[d]咪唑-5-基)-3,5-二甲基异恶唑、含溴结构域蛋白2（Bromodomain-containing protein 2）、甘油（GLYCEROL）。作者：Lansdon, E.B.、Newby, Z.E.R.。提交日期：2018-10-04。发布日期：2019-01-23。最后修改日期：2024-03-13。实验方法：X射线衍射（X-RAY DIFFRACTION，分辨率1.271 Å）。引用文献：《基于结构导向发现新型强效且口服生物可利用的3,5-二甲基异恶唑芳基苯并咪唑类BET溴结构域抑制剂》，Bioorg. Med. Chem., 27, 2019